Activist investor Carl Icahn has dropped a threat to mount a new challenge to Illumina’s board, sparing the U.S. gene sequencing company from its second proxy contest in as many years, people familiar with the matter have told Reuters.
Your donations power the high-quality news San Diego deserves. Help us reach our $10,000 goal by April 10.
Activist investor Carl Icahn has dropped a threat to mount a new challenge to Illumina’s board, sparing the U.S. gene sequencing company from its second proxy contest in as many years, people familiar with the matter have told Reuters.
